Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer
Related Experiment Video
Updated: Jun 1, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Muge Akmansu1, Suleyman Buyukberber, Sevilay Iren
1Department of Radiation Oncology, Gazi University School of Medicine, Ankara, Turkey.
Abstract:
We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall survival analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on this calculation, mean follow-up duration is 12.8 months. Mean survival time is 19.8 months and annual mean survival rate is 59.3%.
Related Concept Videos
Treatment Resistent Cancers
Tumor Immunotherapy
